DENTSPLY Sirona Inc Dossier - Source-backed chat

DENTSPLY Sirona Inc

XRAYNASDAQ

SectorHealth Care

IndustryMedical Instruments & Supplies

Beta (adjusted)0.91

Intrinsic Value $23.92median of 3 methodsbased on filings through 30 Jun 2026

Market Price $8.74Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 174% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+174%)

Data confidence Sign in to view data confidence

Market Cap $1.7B

Enterprise Value $3.7B

Shares Outstanding 201M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

Last ex-dividend26 Dec 2025

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Dentsply Sirona is navigating a critical multi-year turnaround under its 'Return-to-Growth' Action Plan, aimed at streamlining operations, capturing digital dentistry workflows via its cloud-native DS Core platform, and driving $120 million in annual cost savings. While the company's market leadership in dental consumables and equipment remains intact, near-term performance is heavily pressured by the wind-down of the Byte clear aligner business, tariff headwinds, and margin contraction. The elimination of the dividend to prioritize debt reduction and the appointment of John Fortson as the new CFO (effective July 20, 2026) signal aggressive restructuring, but execution risks remain high. A Hold recommendation is warranted until clear signs of margin stabilization and organic top-line recovery emerge.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets16 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$13.59

High · most bullish analyst$17.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$9.0015%

Restructuring efforts face execution delays, and the wind-down of the Byte business causes larger-than-expected revenue leakage. Competitors like Align Technology and Envista capture market share in clear aligners and digital scanners, while high leverage (net debt to EBITDA at 3.3x) and persistent margin contraction limit capital allocation flexibility, forcing further downward revisions to long-term growth estimates.

Base CaseCentral scenario

$13.5960%

Matches the consensus mean

Dentsply Sirona achieves its FY 2026 guidance of $3.5B–$3.6B in net sales and adjusted EPS of $1.40–$1.50. The wind-down of the Byte business and the $30 million drop-ship inventory transition are managed within expected parameters, resulting in flat to slightly negative organic growth. Margins stabilize as cost-saving initiatives offset inflationary and tariff pressures, keeping the stock range-bound near consensus targets.

Bull CaseUpside scenario

$17.0025%

The Return-to-Growth plan successfully delivers $120 million in annual savings, and the migration of users from the retired Connect Case Center to DS Core accelerates high-margin recurring software revenues. Strong adoption of Primescan 2 and AI-driven diagnostic tools drives a rapid turnaround in Clinical Technology Solutions, while aggressive debt paydown de-levers the balance sheet, prompting a valuation re-rating toward historical averages.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Sticky digital ecosystem powered by the DS Core cloud platform, which integrates imaging, diagnostics, and treatment planning across 37,000+ unique accounts.
Aggressive cost-reduction program targeting $120 million in annual savings, with $20 million already realized in Q1 2026.
Strategic leadership transition with the appointment of John Fortson as CFO, bringing extensive public company transformation and capital allocation experience.

Key Investment Risks

Significant near-term revenue and margin headwinds from the wind-down of the Byte clear aligner business and a $30 million drop-ship inventory transition.
Elevated leverage profile with a net debt to EBITDA ratio of 3.3x as of Q1 2026, requiring disciplined cash flow redirection away from dividends.
Intense competitive pressure in the digital dentistry and orthodontic segments from well-capitalized peers like Align Technology and Envista.

Thesis Invalidation Triggers

Failure to achieve the targeted $120 million in annual cost savings or unexpected restructuring cash outflows.
A downward revision of the FY 2026 net sales guidance below the $3.5 billion threshold.
A significant loss of distributor partnerships or rapid market share erosion in North American dental consumables.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.